Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies.
Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, Gurbel PA, Hochholzer W, De Luca L, Bonello L, Aradi D, Cuisset T, Tantry US, Wang TY, Valgimigli M, Waksman R, Mehran R, Montalescot G, Franchi F, Price MJ. Angiolillo DJ, et al. Among authors: so dyf. Circulation. 2017 Nov 14;136(20):1955-1975. doi: 10.1161/CIRCULATIONAHA.117.031164. Epub 2017 Oct 30. Circulation. 2017. PMID: 29084738 Review.
Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST).
Le May MR, Wells GA, Glover CA, So DY, Froeschl M, Marquis JF, O'Brien ER, Turek M, Thomas A, Kass M, Jadhav S, Labinaz M. Le May MR, et al. Circ Cardiovasc Interv. 2009 Aug;2(4):330-8. doi: 10.1161/CIRCINTERVENTIONS.108.847582.108.847582. Epub 2009 Jul 22. Circ Cardiovasc Interv. 2009. PMID: 20031736 Clinical Trial.
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Price MJ, et al. JAMA. 2011 Mar 16;305(11):1097-105. doi: 10.1001/jama.2011.290. JAMA. 2011. PMID: 21406646 Clinical Trial.
A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study.
Hibbert B, Maze R, Pourdjabbar A, Simard T, Ramirez FD, Moudgil R, Blondeau M, Labinaz M, Dick A, Glover C, Froeschl M, Marquis JF, So DY, Le May MR. Hibbert B, et al. PLoS One. 2014 Mar 20;9(3):e92078. doi: 10.1371/journal.pone.0092078. eCollection 2014. PLoS One. 2014. PMID: 24651043 Free PMC article. Clinical Trial.
A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window.
Malhotra N, Abunassar J, Wells GA, McPherson R, Fu A, Hibbert B, Labinaz M, Le May M, Dick A, Glover C, Froeschl M, Marquis JF, Tran L, Bernick J, Chong AY, So DY; CArdiovascular Percutaneous Intervention TriAL (CAPITAL) investigators. Malhotra N, et al. Int J Cardiol. 2015 Oct 15;197:318-25. doi: 10.1016/j.ijcard.2015.06.016. Epub 2015 Jun 15. Int J Cardiol. 2015. PMID: 26151596
136 results